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Background. National notifiable diseases surveillance system (NNDSS) data in developing countries are usually incomplete, 
yet the total number of fatal cases reported is commonly used in national priority-setting. Melioidosis, an infectious disease caused 
by Burkholderia pseudomallei, is largely underrecognized by policy-makers due to the underreporting of fatal cases via the NNDSS.
Methods. Collaborating with the Epidemiology Division (ED), Ministry of Public Health (MoPH), we conducted a retrospec-
tive study to determine the incidence and mortality of melioidosis cases already identified by clinical microbiology laboratories 
nationwide. A case of melioidosis was defined as a patient with any clinical specimen culture positive for B. pseudomallei. Routinely 
available microbiology and hospital databases of secondary care and tertiary care hospitals, the national death registry, and NNDSS 
data were obtained for analysis.
Results. A total of 7126 culture-confirmed melioidosis patients were identified from 2012 to 2015 in 60 hospitals countrywide. 
The total number of cases diagnosed in Northeast, Central, South, East, North, and West Thailand were 5475, 536, 374, 364, 358, and 
19 cases, respectively. The overall 30-day mortality was 39% (2805/7126). Only 126 (4%) deaths were reported to the NNDSS. Age, 
presentation with bacteremia and pneumonia, prevalence of diabetes, and 30-day mortality differed by geographical region (all P < 
.001). The ED at MoPH has agreed to include the findings of our study in the next annual report of the NNDSS.
Conclusions. Melioidosis is an important cause of death in Thailand nationwide, and its clinical epidemiology may be different 
by region. In developing countries, NNDSS data can be supplemented by integrating information from readily available routine data 
sets.
Keywords. notifiable diseases; surveillance system; melioidosis; Burkholderia pseudomallei; epidemiology.
National notifiable diseases surveillance system (NNDSS) data 
are a key part of public health decision-making in all countries, 
including priority-setting, planning, resource mobilization and 
allocation, and monitoring and evaluation of disease preven-
tion and control programs [1]. However, incomplete NNDSS 
data frequently affect priority-setting and actions by policy-
makers, particularly with regards to bacterial diseases in low- 
and middle-income countries (LMICs) [2–4]. In high-income 
countries, the completeness of NNDSS data can range from 
6% to 99%, and invasive bacterial infections are less likely to 
be reported compared with AIDS and tuberculosis [5, 6]. One 
of the solutions for high-income countries is the use of an au-
tomated computerized system to capture a combination of case 
data and laboratory data, create reports, and submit the reports 
to the responsible authority [7–10]. Affordable solutions to im-
prove the completeness and accuracy of NNDSS data in LMICs 
are still needed [11, 12].
Melioidosis, an often fatal infectious disease caused by the 
Gram-negative bacterium Burkholderia pseudomallei, is en-
demic in tropical developing countries [13, 14]. Humans usually 
acquire melioidosis from B. pseudomallei in the environment via 
skin inoculation, ingestion, and inhalation. Diabetes is the most 
common clinical risk factor. The majority of patients present 
with sepsis with or without pneumonia or localized abscesses 
[15]. The mortality of melioidosis cases ranges from 10% to 63% 
[14, 16–18]. A modeling study estimated that there are about 
165 000 melioidosis cases per year worldwide, of which 89 000 
(54%) die [13]. Melioidosis is difficult to diagnose due to non-
specific clinical manifestations and a relative lack of microbio-
logical laboratories in tropical developing countries [14]. The 
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gold standard for the diagnosis of melioidosis is culture [19]. 
B. pseudomallei is not part of the normal human flora, and its 
isolation from any clinical sample is regarded as diagnostic of 
melioidosis. An indirect hemagglutination assay (IHA), which 
detects crude antibodies raised against B. pseudomallei, is nei-
ther sensitive nor specific, and it is not recommended for the 
diagnosis of melioidosis in disease-endemic regions [19].
Although the capacity and utilization of microbiological la-
boratories in public referral hospitals in Thailand are high [20], 
the national burden and epidemiology of melioidosis remain 
poorly understood. The NNDSS was established in Thailand 
in 1968, and melioidosis has been a notifiable disease since 
2002 [2]. About 10 melioidosis deaths have been formally re-
ported to the NNDSS each year [2]. However, a single hospital 
in Northeast Thailand continuously publishes scientific papers 
reporting about 100 fatal melioidosis cases each year [17, 21]. 
A modeling study estimated that there could be about 2800 fatal 
melioidosis cases annually in the country [13]. The low num-
bers of deaths from melioidosis reported to the NNDSS has 
meant that melioidosis has not been prioritized by the Ministry 
of Public Health (MoPH) in Thailand [2]. Here, we aim to de-
termine the incidence, mortality, and clinical epidemiology of 
melioidosis cases already diagnosed by routine clinical microbi-
ological laboratories in all secondary care and tertiary care hos-
pitals in Thailand from 2012 to 2015, compare our findings with 
NNDSS data, and supplement the annual report of the NNDSS 
with our findings.
METHODS
Study Area and Population
In 2012, Thailand had a population of 64.4 million, consisted of 
77 provinces, and covered 513 120 km
2. The country can be di-
vided into 6 geographical regions, comprising Northeast, North, 
East, West, South, and Central [22]. Thai health care services 
are delivered by multiple levels of health care facilities [23]. In 
each province, there are primary care units (PCUs) located in 
subdistricts, community hospitals (district level), and at least 
1 general or regional hospital. Severely ill patients presenting 
to PCUs and community hospitals are often referred to general 
hospitals (acting as secondary care hospitals) or regional hos-
pitals (acting as tertiary care hospitals). In 2012, there were 
68 public general hospitals and 28 public regional hospitals in 
Thailand [24]. Unlike PCUs and community hospitals, these are 
equipped with a microbiology laboratory capable of performing 
bacterial culture using standard methodologies for bacterial 
identification and susceptibility testing provided by the Bureau 
of Laboratory Quality and Standards, MoPH, Thailand [25].
Study Design and Source of Data
Collaborating with the Epidemiology Division (ED) of the 
Department of Disease Control, MoPH, Thailand, we con-
ducted a retrospective, multicenter surveillance study in all 
public general and regional hospitals in Thailand. From the 
hospitals that agreed to participate, data were collected from 
microbiology and hospital databases between January 2012 and 
December 2015. Hospital number (HN) and admission number 
(AN) were used as a record linkage between the 2 databases and 
to identify individuals who had repeat admissions. Diagnoses 
in the hospital data were recorded using 10th revision of the 
International Classification of Disease (ICD) codes. Date of 
death and ICD-10 codes was also extracted from these data.
It is a common in Thailand for terminally ill patients to be 
discharged from hospital to be allowed to die at home [26, 27], 
so 30-day mortality was verified using the death registry data 
of the Ministry of Public Health, Thailand. NNDSS data were 
obtained from the ED, MoPH. The data variables included 
province, type of health care facilities, total number of cases, 
and total number of deaths.
Definitions
Culture-confirmed melioidosis was defined as a patient with 
a culture positive for B.  pseudomallei from any clinical spec-
imen. Comorbidities (diabetes mellitus, hypertension, chronic 
renal failure, chronic obstructive pulmonary disease [COPD], 
chronic liver disease, HIV, tuberculosis, thalassemia, and ma-
lignancy) were defined using ICD-10, Thai edition, codes 
(Supplementary Table 1) [28]. Bacteremia and bacteriuria were 
defined as blood and urine cultures positive for B. pseudomallei, 
respectively. Pneumonia was defined using ICD-10 codes or 
sputum culture positive for the organism. Hepatosplenic ab-
scess, septic arthritis, and osteomyelitis were defined using 
ICD-10 codes.
Thirty-day mortality was determined on the basis of a record 
of death within 30 days of admission in the routine hospital da-
tabase or by a record of death within that period in the national 
death registry. In-hospital mortality was determined using the 
discharge status recorded in the hospital admission data for that 
admission. In the event that a patient had more than 1 episode 
of admission due to culture-confirmed melioidosis, only the 
first episode was included in the study.
Statistical Analysis
The outcomes of interest were incidence and 30-day mortality, 
and their associations with regions, comorbidities, and clinical 
manifestations. The incidence rate (per 100 000 population per 
year) was calculated by dividing the cumulative incidence by the 
total population in the study province. The reporting complete-
ness was calculated by dividing the total number of fatal cases re-
ported by the total number of fatal cases observed. Interquartile 
ranges (IQRs) are presented in terms of 25th and 75th percent-
iles. Binary and continuous variables were compared using 
the chi-square test and Kruskal-Wallis test, respectively. The 
risk factors associated with 30-day mortality were evaluated 
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stratified by hospital. The final multivariable logistic regression 
models were developed using a purposeful selection method 
[29]. Poisson regression models were used to assess changes in 
incidence rates over time and to compare incidence rates among 
regions. All models were stratified by hospital. A sensitivity anal-
ysis was done by evaluating factors associated with in-hospital 
mortality. All statistical analyses were performed using Stata, 
version 15.0 (StataCorp LP, College Station, TX, USA).
Ethical Considerations
Ethical permission for this study was obtained from the Institute 
for the Development of Human Research Protection, Ministry 
of Public Health (IHRP 2334/2556), the Ethics Committee of the 
Faculty of Tropical Medicine, Mahidol University (MUTM 2014-
017-01), and the Oxford Tropical Research Ethics Committee, 
University of Oxford (OXTREC 521-13). Written approval was 
given by the directors of the hospitals to use their routine hos-
pital database for research. Individual consent was not sought 
from the patients as this was a retrospective study, and the 
Ethical and Scientific Review Committees approved the process.
RESULTS
Of 96 public general and regional hospitals in Thailand, 95 
(99%) agreed to participate in the study (Figure 1). Twenty-five 
hospitals (26%) were not included in the analysis because ei-
ther the microbiology or hospital database was not obtained. 
Seventy hospitals included in the analysis were located in 61 
provinces (Figure 2). A total of 54 hospitals (77%) provided data 
for 4 years (from 2012 to 2015), 6 hospitals (9%) for 3 years, 4 
hospitals (6%) for 2 years, and 6 hospitals (8%) for 1 year (see 
supplementary Table 2).
A total of 8 476 596 admission records from 6 228 644 pa-
tients were evaluated, and 7626 admission records had at least 
1 clinical sample culture positive for B. pseudomallei. Multiple 
admissions during which B. pseudomallei was grown from clin-
ical specimens were noted in 421 patients. Only the first episode 
of culture-confirmed melioidosis in 7126 patients was included 
in further analysis.
Incidence of Melioidosis
The total numbers of culture-confirmed melioidosis cases iden-
tified in 2012, 2013, 2014, and 2015 were 1735, 1757, 1932, 
and 1702, respectively (Table 1). Overall, melioidosis cases 
were already diagnosed in 60 hospitals located in 52 provinces 
(Figure 2). The average incidence rate of melioidosis during the 
4-year study period was 3.95 per 100 000 population per year 
and was significantly different by region (P < .001). There was 
no clear trend over the study period. The total number of cases 
diagnosed in Northeast, Central, South, East, North, and West 
Thailand were 5475, 536, 374, 364, 358, and 19 cases, respec-
tively. The incidence rate was highest in Northeast Thailand 
(8.73 per 100  000 population per year) and lowest in West 
Thailand (0.23 per 100  000 population per year; P  <  .001) 
(Supplementary Table 3).
All 96 public provincial and regional hospitals in Thailanda
(located in 77 provinces in Thailand)
95 hospitals agreed to participate in the study
25 hospitals excluded because
of  incomplete data
70 hospitals with paired microbiology and hospital





















Figure 1. Flowchart of the study. aIn 2012, there were 68 public general hospitals (acting as secondary care hospitals) and 28 public regional hospitals (acting as tertiary 
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Figure 2. Incidence rates of culture-confirmed melioidosis in Thailand from 2012 to 2015. Provinces are categorized based on incidence rates of culture-confirmed meli-
oidosis observed (dark red, >5 cases per 100 000 population per year; red, >1–5 cases per 100 000 population per year; yellow, >0–1 cases per 100 000 population per year; 
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Clinical Epidemiology of Melioidosis
Of the 7126 patients, 4839 (68%) were male, and the median age 
(IQR; range) was 54 (44.5–63; <1–100) years (Supplementary 
Table 4). Using ICD-10 codes, we found that the most common 
comorbidities reported were diabetes mellitus (43%), followed 
by hypertension (15%) and chronic kidney disease (11%). The 
most common clinical specimens that were culture positive for 
B. pseudomallei were blood (n = 4910, 69%), sputum (n = 1555, 
22%), urine (n = 341, 5%), pleural fluid (n = 92, 1%), cerebro-
spinal fluid (n = 13, 0.2%), and unidentified pus or fluid (n = 1143, 
16%). Using the combination of ICD-10 codes and the microbi-
ology laboratory database, we found that the most common clin-
ical presentation was bacteremia (69%), followed by pneumonia 
(38%), hepatosplenic abscesses (8%), and bacteriuria (5%).
Age, comorbidities, and clinical presentations of melioidosis 
in Thailand differed by geographical region (Supplementary 
Table 4). The median age of patients was highest in North 
Thailand (57  years) and lowest in West Thailand (48  years; 
P  <  .001). The prevalence of diabetes mellitus was highest in 
South Thailand (48%) and lowest in North Thailand (21%; 
P  <  .001). Presentation with bacteremia was highest in East 
Thailand (78%) and lowest in West Thailand (63%). Presentation 
with pneumonia was also highest in East Thailand (46%) and 
lowest in West Thailand (16%).
Mortality Involving Melioidosis
A total of 2805 cases died within 30 days of hospital admission, 
giving a 30-day mortality of 39% (2805/7126). Death in meli-
oidosis patients often occurred rapidly, with 1076 deaths (39%) 
occurring within the first 2 days of admission, 894 (32%) from 
day 3 to day 7, and the remaining 835 (30%) after 7  days of 
admission.
In the univariable logistic regression models, 30-day mortality 
was associated with older age, comorbidities, clinical presentation, 
and region (Supplementary Table 5). In the final multivariable 
model, 30-day mortality was associated with the comorbidities 
of chronic kidney disease and liver disease, and presentation with 
bacteremia, pneumonia, and bacteriuria (Table 2). Male gender, 
comorbidities of diabetes and thalassemia, and presentation with 
hepatosplenic abscesses, septic arthritis, and osteomyelitis were 
associated with survival. Sensitivity analysis showed that factors 
associated with in-hospital mortality were similar to factors as-
sociated with 30-day mortality, except that some P values were 
slightly higher (Supplementary Tables 6 and 7).
Comparison Between Hospital Data and NNDSS Data
The total number of melioidosis cases reported to the NNDSS 
during the study period was 12 305, of which 141 were reported 
as fatal cases (Table 3). Of 2805 fatal melioidosis cases identified 
by the microbiology and hospital databases of the participating 
hospitals during the study period, 126 were reported as fatal 
cases to Report 506, giving a completeness of 4% (126/2805).
Policy-Maker Engagement
The findings of our study were reported to the ED, MoPH, 
which agreed to include the findings in the next annual report 
of the NNDSS.
DISCUSSION
Using routine microbiology and hospital databases, we show that 
in Thailand each year, about 1700 culture-confirmed melioid-
osis cases are diagnosed, of whom approximately 700 die. Only 
about 4% of the deaths were reported to the NNDSS Thailand. 
Integrating information from readily available microbiology 
and hospital data can reveal the burden of underreported noti-
fiable diseases. This information could support priority-setting 
by policy-makers in LMICs. We propose, therefore, that inte-
grating information from readily available data sets to improve 
national statistics and NNDSS data in LMICs should be con-
sidered and implemented.
We expect that including the findings of our study in the 
next annual report of the NNDSS could support initiatives to-
ward a National Programme for Melioidosis to improve aware-
ness, surveillance, diagnosis, treatment, and prevention of 
Table 1. Total Number of Culture-Confirmed Melioidosis Cases Diagnosed by Routine Clinical Microbiology Laboratories in Public Secondary Care and 
Tertiary Care Hospitals in Thailand in 2012 to 2015
Regions No. of Participating Hospitals No. of Provincesa
No. of Culture-Confirmed Melioidosis Casesb
2012 2013 2014 2015 Total
Northeast 17 17 1332 1359 1481 1303 5475
Central 21 17 112 142 155 127 536
South 12 10 97 75 95 107 374
East 5 5 85 84 113 82 364
North 9 8 99 93 85 81 358
West 6 4 10 4 3 2 19
Total 70 61 1735 1757 1932 1702 7126
aEight provinces had the data obtained from more than 1 hospital, including Lopburi (2), Phang Nga (2), Phayao (2), Ratchaburi (3), Saraburi (2), Singburi (2), Songkhla (2), and Suphanburi (2).
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melioidosis by MoPH Thailand. Our finding of deaths involving 
melioidosis (about 700 fatal cases per year) is much higher than 
the mortalities involving dengue infection (about 100 fatal cases 
per year) shown in the annual report of the NNDSS Thailand 
[2]. In Thailand, dengue infection is considered high priority 
by policy-makers. There is a National Programme for Dengue 
Prevention Control focused on empowering individuals and 
communities for source reduction, health promotion, medical 
services, multisectoral networking, and enhancing capacity-
building [30]. These activities improve dengue diagnosis and 
reporting, and most, if not all, diagnosed fatal cases are reported 
via the NNDSS.
Underreporting to the NNDSS could occur for a range of 
reasons. First, persons who are responsible for reporting noti-
fiable diseases in many hospitals with microbiology laboratories 
(including epidemiologists, nurses, and doctors [31]) do not 
know that they should confirm a fatal outcome of all culture-
confirmed melioidosis cases and report the death of any patients 
with culture-confirmed melioidosis to the NNDSS [2]. Second, 
laboratory isolation and identification of B. pseudomallei can take 
from 2 to 7 days, and many melioidosis cases could die before the 
culture results. In such cases, nurses and physicians would not be 
aware of the causative pathogen, and epidemiologists in the hos-
pitals would not be informed and would not report the cases to 
the NNDSS [31]. Third, the definition of melioidosis used for the 
NNDSS Thailand is broad. The NNDSS Thailand recommends 
that both probable and confirmed melioidosis cases be reported 
[2]. Probable cases are defined as clinically compatible illness 
with an IHA titer ≥1:160 or immunofluorescence antibody test 
(IFA) >1:400. Confirmed melioidosis cases are defined as clini-
cally compatible illness with any clinical specimen culture posi-
tive for B. pseudomallei or a 4-fold rise in IHA or IFA. However, 
IFA and IHA are not recommended for diagnosing melioidosis 
in disease-endemic areas; these tests are neither sensitive nor 
specific [19]. More than 60% of melioidosis cases reported to 
Report 506 are from PCUs or community hospitals that do not 
have microbiology laboratories, and a proportion of these re-
ported cases are likely to be false-positive cases (ie, cases who do 
not have melioidosis but tested IFA or IHA positive due to pre-
vious exposure to environmental B. pseudomallei [19]).
Evaluating the incidence, mortality, and clinical epidemi-
ology of a notifiable disease among provinces could give new 
information about diseases and highlight areas where diagnosis 
or reporting systems may need additional investigation. For ex-
ample, culture-confirmed melioidosis cases were not identified 
in 9 provinces (10 hospitals) participating in our study, but a 
high incidence of culture-confirmed melioidosis cases was ob-
served in neighboring provinces in our study. It is possible that 
Table 2. Factors Associated With 30-Day Mortality in 7126 Culture-Confirmed Melioidosis Cases in 2012–2015, by Multivariable Logistic Regression 
Model, Stratified by Hospital
Baseline Characteristics Died (n = 2805) Survived (n = 4321) Adjusted Odds Ratio(95% CI) P
Gender (male), No. (%) 1908 (68.0) 2931 (67.8) 0.84 (0.74–0.94) .004
Age, median (IQR), y 56 (46–65) 53 (43–61) 1.01 (1.01–1.02) <.001
Comorbidities,a No. (%)     
 Liver disease 371 (13.2) 290 (6.7) 1.89 (1.57–2.28) <.001
 Chronic kidney disease 410 (14.6) 405 (9.4) 1.54 (1.30–1.83) <.001
 Thalassemia 36 (1.3) 115 (2.7) 0.60 (0.38–0.92) .02
 Diabetes mellitus 1061 (37.8) 1984 (45.9) 0.57 (0.50–0.64) <.001
Clinical manifestations, No. (%)
 Bacteremiab 2391 (85.2) 2519 (58.3) 5.66 (4.93–6.51) <.001
 Pneumoniac 1574 (56.1) 1131 (26.2) 4.44 (3.94–4.99) <.001
 Bacteriuriad 209 (7.5) 132 (3.1) 3.14 (2.41–4.09) <.001
 Hepatosplenic abscesse 100 (3.6) 480 (11.1) 0.35 (0.28–0.45) <.001
 Septic arthritise 85 (3.0) 300 (6.9) 0.61 (0.46–0.81) .001
 Ostemomyelitise 6 (0.2) 57 (1.3) 0.36 (0.14–0.91) .03
Regions, No. (%)     
 Northeast 2190 (78.1) 3285 (76.0) 1 .05
 Central 215 (7.7) 321 (7.4) 0.95 (0.72–1.25)  
 East 158 (5.6) 206 (4.8) 0.91 (0.66–1.25)  
 North 111 (4.0) 247 (5.7) 0.60 (0.43–0.84)  
 South 129 (4.6) 245 (5.7) 0.87 (0.64–1.17)  
 West 2 (0.1) 17 (0.4) 0.26 (0.06–1.24)  
Abbreviations: CI, confidence interval; IQR, interquartile range.
aComorbidities identified by using the ICD-10 codes listed in Supplementary Table 1.
bBlood culture positive for B. pseudomallei.
cUsing ICD-10 codes or sputum culture positive for B. pseudomallei.







/ofid/article-abstract/6/12/ofz498/5629151 by guest on 01 June 2020
Clinical Epidemiology of 7126 Melioidosis Patients in Thailand • ofid • 7
B. pseudomallei may be misidentified as Pseudomonas spp. or 
that there may be contaminants in the laboratories in those 
provinces. This suggests that evaluation of protocols and oper-
ating procedures in microbiological laboratories in these prov-
inces may be warranted.
The differences in clinical presentations and mortality 
of melioidosis across geographical regions could be due to 
several reasons, including differing characteristics of the 
baseline population, differences in the distribution of envi-
ronmental B.  pseudomallei [32, 33], virulence characteristics 
of B. pseudomallei [34], variation in risk of exposure and route 
of infection related to occupational activities [14, 35], and dis-
parity among practices of physicians and clinical microbio-
logical laboratories in the region. Selective culture media for 
B. pseudomallei, which can increase the sensitivity of bacterial 
isolation from nonsterile specimens such as sputum and urine, is 
only used in a limited number of hospitals in Northeast Thailand 
[2]. Variation in clinical presentations and comorbidities could 
also be due to different practices in recording ICD-10 codes by 
trained ICD coders or attending physicians in each region. This 
suggests that training for laboratory personnel and clinicians, 
informing clinicians of possible variation in clinical presenta-
tion of melioidosis cases, and workshops to improve communi-
cation between laboratory personnel, clinicians, ICD-10 coders, 
and persons responsible for NNDSS reporting should be pro-
vided countrywide. Further studies on differences in clinical 
presentations and mortality of melioidosis across regions are 
also required.
The lower overall mortality of patients with diabetes could be 
due to the use of glibenclamide [14, 36]. This has an anti-inflam-
matory effect, and patients taking glibenclamide before hospital 
admission have attenuated inflammatory responses [14, 36]. 
The lower overall mortality of patients with thalassemia could 
be due to early diagnosis of melioidosis in patients with a major 
underlying disease, unknown reasons (eg, increasing utilization 
of iron chelation therapy in Thailand), or residual confounding 
factors. Patients with thalassemia were reported to have a high 
mortality (59%, 16/28) in Sabah, Malaysia, and the incidence 
of melioidosis has decreased considerably since the universal 
availability of iron chelation therapy [37].
We propose a set of low-cost actions to improve NNDSS data 
in LMICs, including (1) routinely utilizing all laboratory data-
bases (including microbiology, serology, and rapid diagnostic 
test databases) and hospital databases from all public and private 
hospitals to supplement NNDSS data of all notifiable diseases, 
(2) providing training to laboratory personnel countrywide to 
improve the sensitivity and accuracy of laboratory-diagnosed 
cases, (3) raising awareness among health care providers about 
Table 3. Comparison Between Incidences and Mortalities of Melioidosis Diagnosed by Microbiology Laboratories and Those Officially Reported to the 
National Notifiable Disease Surveillance System (Report 506) in Thailand From 2012 to 2015
 Year  Type of Hospital
Culture-Confirmed Melioidosisa Report 506 Datab
No. of Cases Diag-
nosed
No. of Mortality 
Outcome
No. of Cases  
Reported
No. of Mortality  
Outcome Reported
2012 PCUs or community hospitals NA NA 2426 2
 Regional or general hospitals not included 
in the study 
NA NA 259 7
 Regional or general hospital included in 
the study 
1735 683 1018 4
2013 PCUs or community hospitals NA NA 1821 0
 Regional or general hospitals not included 
in the study 
NA NA 210 1
 Regional or general hospital included in 
the study 
1757 737 799 3
2014 PCUs or community hospitals NA NA 1677 3
 Regional or general hospitals not included 
in the study 
NA NA 174 1
 Regional or general hospital included in 
the study 
1932 750 695 8
2015 PCUs or community hospitals NA NA 2042 1
 Regional or general hospitals not included 
in the study 
NA NA 217 0
 Regional or general hospital included in 
the study 
1702 635 967 111 c
Abbreviations: IHA, indirect hemagglutination assay; PCU, primary care unit.
aSeventy of 96 public general and regional hospitals in Thailand participated in the study. 
bBased on the national notifiable disease surveillance system in Thailand. Both probable and confirmed melioidosis cases are reported. Probable cases are defined as clinically compatible 
illness with IHA titer ≥1:160 or IFA >1:400. Confirmed melioidosis cases are defined as clinically compatible illness with any clinical specimen culture positive for B. pseudomallei or a 4-fold 
rise in IHA or IFA. 
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diagnostic criteria and requirements for reporting the final 
outcome of all cases with notifiable diseases, and (4) updating 
criteria for diagnosing and reporting notifiable diseases. For ex-
ample, patients culture positive for B. pseuodmallei should be 
defined as “culture-confirmed melioidosis cases” and reported 
to the NNDSS, similar to systems in Singapore, Australia, and 
Taiwan [38–40]. Melioidosis cases diagnosed based on the IHA 
or IFA without culture confirmation should be defined as “pos-
sible melioidosis cases” when reported to the NNDSS Thailand. 
These actions are being implemented or discussed with the ED, 
MoPH Thailand, in conjunction with the current NNDSS.
The difference between the observed 701 fatal culture-
confirmed melioidosis cases pear year in this study and the 
predicted 2838 fatal melioidosis cases per year in the previous 
modeling study [13] could be due to multiple reasons. First, 
only 74% of public general and regional hospitals in Thailand 
were included in the study, and only 77% of those hospitals pro-
vided data for all 4 years. Therefore, our data represented only 
about two-thirds of the already diagnosed melioidosis patients 
in Thailand. Second, it is possible that the participating hospitals 
may still misidentify a proportion of the B. pseudomallei isolates 
as contaminants or other bacteria [19]. Although it is possible 
that other bacteria could be misidentified as B. pseudomallei, we 
believe that it is rare based on the increasing clinical informa-
tion and bacterial confirmation of melioidosis cases in all re-
gions [2]. Third, the modeling study was based on data from 
large hospitals with research facilities, where the blood culture 
utilization rate is already high [20] and selective culture media 
for B. pseudomallei are used for nonsterile specimens collected 
from melioidosis-suspected cases [13, 19]. It is likely that some 
public general and regional hospitals will find more melioidosis 
cases if culturing practices change and selective culture media 
are used for melioidosis-suspected cases [16, 17]. Therefore, 
the number of cases and deaths from melioidosis reported here 
could represent a minimum estimate. Fourth, the previous 
model was imprecise, as shown by the wide 95% credible in-
terval of the predicted mortality (1259 to 6678) due to limited 
data availability at that time [13]. The model could be revised 
and improved by using increasingly available data in the future.
The limitations of this study are that private hospitals, spe-
cialized hospitals such as military hospitals and psychiatric hos-
pitals, hospitals in Bangkok, and university hospitals were not 
included in the study. The lack of culture-confirmed melioidosis 
identified in certain provinces should be interpreted with cau-
tion; an absence of risk for melioidosis acquisition in these areas 
should not be implied.
In conclusion, the high number of deaths from melioid-
osis reported in our study provides policy-makers with the 
evidence they need to accord a high priority to melioidosis 
as a major health problem in Thailand. Integrating informa-
tion from readily available microbiology and hospital data-
bases could be used to generate such information, supplement 
NNDSS data, and support priority-setting for policy-makers 
in LMICs.
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